Insulin - Administration & dosage
Research News and Information

Saturday, November 21, 2009

A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial).

30 Oct 2009 PURPOSE: To study glycemic control and hypoglycemia development upon initiation of insulin through a self-titration schedule in a 24-week trial, conducted with 4875 insulin-naïve patients with poorly controlled type 2 diabetes, predominantly in a ... Read more...

Three-year efficacy of complex insulin regimens in type 2 diabetes.

20 Oct 2009 BACKGROUND: Evidence supporting the addition of specific insulin regimens to oral therapy in patients with type 2 diabetes mellitus is limited. METHODS: In this 3-year open-label, multicenter trial, we evaluated 708 patients who had suboptimal ... Read more...

Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine.

29 Sep 2009 Recent reports have described different risks of acute myocardial infarction (AMI) in association with specific oral antidiabetic medications. The present study compared the AMI incidence rates in new users of traditional neutral protamine Hagedorn ... Read more...

Latest indexed articles for 'Insulin - Administration & dosage'

These are the very latest articles for this heading:

• Images in clinical medicine. Injection-site lipoatrophy. 3 Nov 2009
• All glucose measurements are not equal. 30 Oct 2009
• A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial). 30 Oct 2009
• Insulin drips or glucose control for burn patients. 30 Oct 2009
• Three-year efficacy of complex insulin regimens in type 2 diabetes. 20 Oct 2009
• Optimal insulin treatment in type 2 diabetes. 20 Oct 2009
• Could insulin sensitization be used as an alternative to intensive insulin therapy to improve the survival of intensive care unit patients with stress-induced hyperglycemia? 29 Sep 2009
• Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine. 29 Sep 2009
• Who should administer insulin in schools? Sorting out the controversy. 26 Sep 2009
• Is insulin the preferred compound in lowering glucose levels in patients after a myocardial infarction? 26 Sep 2009
• Early use of high-dose insulin euglycaemic therapy for verapamil toxicity. 19 Sep 2009
• Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. 14 Sep 2009
• Glycaemic control in patients with type 1 diabetes after provision of public hospital-funded insulin pumps. 5 Sep 2009
• Intensive insulin therapy confers a similar survival benefit in the burn intensive care unit to the surgical intensive care unit. 3 Sep 2009
• The use of high-dose insulin-glucose euglycemia in beta-blocker overdose: a case report. 30 Aug 2009
• Stealth nanoparticles coated with heparin as peptide or protein carriers. 30 Aug 2009
• The NICE-SUGAR and RENAL statistical analysis plans. 30 Aug 2009
• Effect of insulin on airway responsiveness in patients with type 2 diabetes mellitus: a cohort study. 30 Aug 2009
• Hypoglycemia with intensive insulin therapy in critically ill patients: predisposing factors and association with mortality. 30 Aug 2009
• Hypoglycemia and intensive insulin therapy: strict vigilance and prompt correction. 30 Aug 2009

See a longer list of these articles.

Technical information about 'Insulin'

Definition: A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).

Chemical name: Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-

Registry Number: 11061-68-0

Descriptor UI: D007328

Alternative terms: Insulin; Insulin, Regular; Regular Insulin; Humulin S; Iletin; Insulin A Chain; Insulin, Globin Zinc; Globin Zinc Insulin; Velosulin; Insulin, Regular, Human; Insulin, Regular, Pork; Novolin; Sodium Insulin; Insulin, Sodium; Type I Insulin; Insulin, Type I; Type II Insulin; Insulin, Type II; Humulin; Insulin, Regular, Beef-Pork;

Related Mesh Headings: Hyperinsulinism; Nonsuppressible Insulin-Like Activity; Proinsulin; Receptor, Insulin;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Hypoglycemic Agents;

Tree Number: D06.472.699.587.740.625; D12.644.548.586.740.625;

Technical Notes: /blood: consider also HYPERINSULINEMIA (excessively high blood insulin levels) but do not confuse with HYPERINSULINISM (excessive secretion of insulin by pancreas); /immunology: consider also INSULIN ANTIBODIES; precursor = PROINSULIN; INSULIN INFUSION SYSTEMS is available